Brazilian Journal of Anesthesiology
Brazilian Journal of Anesthesiology
Narrative Review

Cannabis and pain: a scoping review

Cannabis e dor: uma revisão de escopo

Camila Pantoja-Ruiz; Paula Restrepo-Jimenez; Camilo Castañeda-Cardona; Alexandra Ferreirós; Diego Rosselli

Downloads: 0
Views: 784


Abstract: For centuries, cannabis has been used with many different purposes, including medicinal use, usually bypassing any formal approval process. However, during the last decade, interest in cannabis in medicine has been increasing, and several countries, including the United States and Canada, have produced their own legislation about marihuana and cannabis-based medicines. Because of this, interest in research has been increasing and evidence about its medical effects is becoming necessary. We conducted a review examining the evidence of cannabis in pain. Cannabis had been shown to be useful in acute and chronic pain, however recently, these results have been controverted. Within the different types of chronic pain, it has a weak evidence for neuropathic, rheumatic pain, and headache, modest evidence for multiple sclerosis related pain, and as adjuvant therapy in cancer pain. There is no strong evidence to recommend cannabis in order to decrease opioids in patients with chronic use. Even though cannabis-based medications appear to be mostly safe, mild adverse effects are common; somnolence, sedation, amnesia, euphoric mood, hyperhidrosis, paranoia, and confusion may limit the use of cannabis in clinical practice. Risks have not been systematically analyzed. Special concern arises on how adverse effect might affect vulnerable population such as elderly patients. More research is needed in order to evaluate benefits and risks, as well as the ideal administration route and dosages. As cannabis use increases in several countries, answers to these questions might be coming soon.


Acute pain, Cannabis, Neuralgia, Review, Chronic pain, Cancer pain


Por séculos, a cannabis tem sido usada com muitos propósitos diferentes, incluindo o uso medicinal, geralmente contornando qualquer processo de aprovação formal. No entanto, durante a última década, o interesse pela cannabis na medicina tem aumentado, e vários países, incluindo os Estados Unidos e o Canadá, produziram sua própria legislação sobre a maconha e os medicamentos à base de cannabis. Por conta disso, o interesse por pesquisas vem crescendo examinando as evidências de cannabis na dor. A cannabis demonstrou ser útil na dor aguda e crônica, no entanto, recentemente, esses resultados foram controversos. Entre os diferentes tipos de dor crônica, tem uma evidência fraca para dor neuropática, reumática e cefaleia, evidência modesta para dor relacionada à esclerose múltipla e como terapia adjuvante na dor oncológica. Não há evidências fortes para recomendar cannabis a fim de diminuir os opioides em pacientes com uso crônico. Embora os medicamentos à base de cannabis pareçam ser em sua maioria seguros, efeitos adversos leves são comuns; sonolência, sedação, amnésia, humor eufórico, hiperidrose, paranoia e confusão podem limitar o uso de cannabis na prática clínica. Os riscos não foram analisados sistematicamente. Uma preocupação especial surge sobre como o efeito adverso pode afetar a população vulnerável, como pacientes idosos. Mais pesquisas são necessárias para avaliar benefícios e riscos, bem como a via e dosagens ideais de administração. Como o uso de cannabis aumenta em vários países, as respostas a essas perguntas podem chegar em breve.



Dor aguda, Cannabis, Neuralgia, Análise, Dor crônica, Dor de câncer


1 Hill KP, Palastro MD, Johnson B, et al. Cannabis and pain: a clinical review. Cannabis Cannabinoid Res. 2017;2:96-104.

2 Touw M, Arboretum A. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981;13:23-34.

3 Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28:153-7.

4 Mikuriya T. Marijuana in medicine: past, present and future. Calif Med. 1969;110:34-40.

5 Bowen LL, McRae-Clark AL. Therapeutic benefit of smoked cannabis in randomized placebo-controlled studies. Pharmacotherapy. 2018;38:80-5.

6 Jensen B, Chen J, Furnish T, et al. Medical marijuana and chronic pain: a review of basic science and clinical evidence. Curr Pain Headache Rep. 2015;19:50.

7 Grotenhermen F, Russo E. Cannabis and cannabinoids: pharmacology, toxicology and therapeutic potential. Psychology Press; 2002.

8 Fitzcharles MA, Eisenberg E. Medical cannabis: a forward vision for the clinician. Eur J Pain. 2018;22:485-91.

9 National Conference of State Legislatures. State medical marijuana laws; 2016.

10 Lynch ME. Cannabinoids in the management of chronic pain: a front line clinical perspective. J Basic Clin Physiol Pharmacol. 2016;27:189-91.

11 Hauser W, Fitzcharles M-A, Radbruch L, et al. Cannabinoids in pain management and palliative medicine. Dtsch Arztebl Int. 2017;114:627-34.

12 Pertwee R. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147:S163-71.

13 Demuth D, Molleman A. Cannabinoid signaling. Life Sci. 2006;78:549-63.

14 Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-7.

15 Ljubiˇsa G. A comparative study on some chemical and biological characteristics of various samples of cannabis resin. Bull Narc. 1962;3, 37.6.

16 Amin MR, Ali DW. Pharmacology of medical cannabis. Adv Exp Med Biol. 2019;1162:151-65.

17 Pascual D, Sanchez-Robles EM, Garcia MM, et al. Chronic pain and cannabinoids. Great expectations or a christmas carol. Biochem Pharmacol. 2018;157:33-42.

18 Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4:245-59.

19 Steiner M, Wotjak CT. Role of the endocannabinoid system in regulation of the hypothalamic-pituitary-adrenocortical axis. Prog Brain Res. 2008;170:397-432.

20 Starowicz K, Malek N, Przewlocka B. Cannabinoid receptors and pain. Wiley Interdiscip Rev Membr Transp Signal. 2013;2:121-32.

21 Urits I, Borchart M, Hasegawa M, et al. An update of current cannabis-based pharmaceuticals in pain medicine. Pain Ther. 2019;8:41-51.

22 Howlett AC. A short guide to the nomenclature of seventrans- membrane spanning receptors for lipid mediators. Life Sci. 2005;77AD:1522-30.

23 Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147:S163-71.

24 Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 2006;30:S13-8.

25 Mlezack R, Wall P. Pain mechanisms: a new theory. Science (80-). 1965;150:971-9.

26 Koenig J, Werdehausen R, Linley JE, et al. Regulation of Nav1.7: a conserved SCN9A natural antisense transcript expressed in dorsal root ganglia. PLoS One. 2015;10:1-14.

27 Kremer M. Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights. Neuroscience. 2016;338:183-206.

28 Arnold LM, Choy E, Clauw DJ, et al. Fibromyalgia and chronic pain syndromes: A white paper detailing current challenges in the field. Clin J Pain. 2016;32:737-46.

29 Starowicz K, Finn DP. Cannabinoids and pain: sites and mechanisms of action. Adv Pharmacol. 2017;80:437-75.

30 Cheng Y, Hitchcock S. Targeting cannabinoid agonists for inflammatory and neuropathic pain. Expert Opin Investig Drugs. 2007;16:951-65.

31 Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 1999;822:17-25.

32 Farquhar-Smith WP, Egertova M, Bradbury EJ, et al. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci. 2000;15:510-21.

33 De Vry J, Jentzsch KR, Kuhl E, et al. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol. 2004;15:1-12.

34 Derbenev AV, Stuart TC, Smith BN. Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J Physiol. 2004;559:923-38.

35 Ashton JC, Friberg D, Darlington CL, et al. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett. 2006;396:113-6.

36 Malfait A, Gallily R, Sumariwalla P, et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97:9561-6.

37 Njoo C, Agarwal N, Lutz B, et al. The cannabinoid receptor CB1 interacts with the WAVE1 complex and plays a role in actin dynamics and structural plasticity in neurons. PLoS Biol. 2015;13:1-36.

38 Martin WJ, Patrick SL, Coffin PO, et al. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 1995;56:2103-9.

39 Hsieh GC, Pai M, Chandran P, et al. Central and peripheral sites of action for CB 2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol. 2011;162:428-40.

40 Monhemius R, Azami J, Green DL, et al. CB1 receptor mediated analgesia from the nucleus reticularis gigantocellularis pars alpha is activated in an animal model of neuropathic pain. Brain Res. 2001;908:67-74.

41 Escobar W, Ramirez K, Avila C, et al. Metamizol, a non-opioid analgesic, acts via endocannabinoids in the PAG-RVM axis during inflammation in rats. Eur J Pain. 2012;16:676-89.

42 Ji G, Neugebauer V. CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model. Eur J Neurosci. 2012;1: 233-45.

43 Elmes SJR, Jhaveri MD, Smart D, et al. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci. 2004;20:2311-20.

44 Strangman NM, Walker JM. Cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J Neurophysiol. 1999;82:472-7.

45 Petrosino S, Palazzo E, de Novellis V, et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology. 2007;52:415-22.

46 Lim G, Sung B, Ji RR, et al. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003;105:275-83.

47 Beaulieu P. Cannabinoids for postoperative pain. Anesthesiology. 2007;106:397.

48 Holdcroft A, Maze M, Doré C, et al. A multicenter doseescalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology. 2006;104:1040-6.

49 Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral 3-9-tetrahydrocannabinol in postoperative pain. Pain. 2003;106:169-72.

50 Beauliu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anesth. 2006;53:769-75.

51 Raft D, Gregg J, Ghia J, et al. Effects of intravenous tetrahydrocannabinol on experimental and surgical pain: psychological correlates of the analgesic response. Clin Pharmacol Ther. 1977;21:26-33.

52 Jain A, Ryan J, McMahon G, et al. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 1981;21, 320S-6.

53 Aziz Q, Barke A, Bennett MI, et al. A classification of chronic pain for ICD-11. Pain. 2015;156:1003-7.

54 Johal H, Devji T, Chang Y, et al. Cannabinoids in chronic non-cancer pain: a systematic review and meta-analysis. Clin Med Insights Arthritis Musculoskelet Disord. 2020;13, 1179544120906461.

55 Jensen T, Baron R, Haanpää M, et al. A new definition of neuropathic pain. Pain. 2011;152:2205-6.

56 Mucke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane database Syst Rev. 2018;3:1-102.

57 Lunn M, Hughes R, Wiffen P. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014:CD007115.

58 Moore R, Straube S, Wiffen P, et al. Pregabalin for acute and chronic pain in adults. Cochrane Database Syst Rev. 2009:CD007076.

59 Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebocontrolled trial. Neurology. 2007;68:515-21.

60 Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropharmacology. 2011;34:672-80.

61 Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ. 2010;182:E694-701.

62 Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2016;15:477-91.

63 Wilsey B, Marcotte T, Tsodikov A, et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008;9:506-21.

64 Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573-81.

65 Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: systematic review, metaanalysis and updated NeuPSIG recommendations. Lancet Neurol. 2016;14:162-73.

66 Rice J, Cameron M. Cannabinoids for treatment of MS symptoms: state of the evidence. Curr Neurol Neurosci Rep. 2018;18:50.

67 Akgün K, Essner U, Seydel C, et al. Daily practice managing resistant multiple sclerosis spasticity with delta-9-tetrahydrocannabinol: Cannabidiol oromucosal spray: a systematic review of observational studies. J Cent Nerv Syst Dis. 2019;11, 1179573519831997.

68 Colfield S, Salter A, Tyry T, et al. Perspectives on marijuana use and effectiveness. Neurol Clin Pract. 2017;7:333-43.

69 Foley PL, Vesterinen HM, Laird BJ, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154:632-42.

70 Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76:1664-9.

71 Zajicek JP, Hobart JC, Slade A, et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125-32.

72 Turcotte D, Doupe M, Torabi M, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med (United States). 2015;16:149-59.

73 Lynch ME, Ware MA. Cannabinoids for the Treatment of chronic non-cancer pain: an updated systematic review of randomized controlled trials. J Neuroimmune Pharmacol. 2015;10:293-301.

74 Iskedjian M, Bereza B, Gordon A, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23:17-24.

75 Fitzcharles M-A, Baerwald C, Ablin J, et al. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): a systematic review of randomized controlled trials. Schmerz. 2016;30: 47-61.

76 Fitzcharles M-A, Hauser W. Cannabinoids in the management of musculoskeletal or rheumatic diseases. Curr Rheumatol Rep. 2016;18:76.

77 Gonen T, Amital H. Cannabis and cannabinoids in the treatment of rheumatic diseases. Rambam Maimonides Med J. 2020;11:e0007.

78 Richardson D, Pearson RG, Kurian N, et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther. 2008;10:1-14.

79 Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology. 2006;45:50-2.

80 Skrabek RQ, Galimova L, Ethans K, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9:164-73.

81 Pinsger M, Schimetta W, Volc D, et al. Nutzen einer Add-On-Therapie mit dem synthetischen Cannabinomimetikum Nabilone bei Patienten mit chronischen Schmerzzuständen -Eine randomisierte kontrollierte Studie. Wien Klin Wochenschr. 2006;118:327-35.

82 Fitzcharles M-A, Ste-Marie PA, Hauser W, et al. Efficacy, Tolerability, and safety of cannabinoid treatments in the rheumatic diseases: a systematic review of randomized controlled trials. Arthritis Care Res (Hoboken). 2016;68:681-8.

83 Walitt B, Klose P, Fitzcharles M-A, et al. Cannabinoids for fibromyalgia. Cochrane database Syst Rev. 2016;7:CD011694.

84 Van Den Beuken-Van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, et al. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51, 1070-1090.e9.

85 Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001;93:247-57.

86 Tateo S. State of the evidence: cannabinoids and cancer pain-A systematic review. J Am Assoc Nurse Pract. 2017;29:94-103.

87 Liang SY, Wu SF, Chao TC, et al. The impact of pain on the quality of life of Taiwanese oncology patients. Pain Manag Nurs. 2015;16:128-36.

88 Wong SSC, Chan WS, Cheung CW. Analgesic effects of cannabinoids for chronic non-cancer pain: a systematic review and meta-analysis with meta-regression. J Neuroimmune Pharmacol. 2020;15:801-29.

89 Johnson JR, Burnell-Nugent M, Lossignol D, et al. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39:167-79.

90 Johnson JR, Lossignol D, Burnell-Nugent M, et al. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46:207-18.

91 Portenoy RK, Ganae-Motan ED, Allende S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13:438-49.

92 Lichtman AH, Lux EA, McQuade R, et al. Results of a double-blind, randomized, placebo-controlled study of nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage. 2018;55, 179-188.e1.

93 Brisbois TD, de Kock IH, Watanabe SM, et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial. Ann Oncol. 2011;22:2086-93.

94 Levy C, Galenbeck E, Magid K. Cannabis for symptom management in older adults. Med Clin North Am. 2020;104:471-89.

95 Hu XH. Burden of migraine in the United States. Arch Intern Med [Internet]. 1999;159:813.

96 Lochte BC, Beletsky A, Samuel NK, et al. The Use of cannabis for headache disorders. Cannabis Cannabinoid Res. 2017;2:61-71.

97 Rhyne DN, Anderson SL, Gedde M, et al. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacotherapy. 2016;36:505-10.

98 Robbins MS, Tarshish S, Solomon S, et al. Cluster attacks responsive to recreational cannabis and dronabinol. Headache. 2009;49:914-6.

99 Leroux E, Taifas I, Valade D, et al. Use of cannabis among 139 cluster headache sufferers. Cephalalgia. 2013;33:208-13.

100 Pini LA, Guerzoni S, Cainazzo MM, et al. Nabilone for the treatment of medication overuse headache: Results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain. 2012;13:677-84.

101 Calcaterra S, Glanz J, Binswanger IA. National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend. 2013;131:263-70.

102 Abrams DI, Guzman M. Cannabis in cancer care. Clin Pharmacol Ther. 2015;97:575-86.

103 Khan SP, Pickens TA, Berlau DJ. Perspectives on cannabis as a substitute for opioid analgesics. Pain Manag. 2019;9:191-203.

104 Abrams DI, Couey P, Shade SB, et al. Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther. 2011;90:844-51.

105 Bachhuber MA, Saloner B, Cunningham CO, et al. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174:1668-73.

106 Ware MA, Wang T, Shapiro S, et al. Cannabis for the management of pain: Assessment of Safety Study (COMPASS). J Pain. 2015;16:1233-42.

107 Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017;167:319-31.

108 Minerbi A, Hauser W, Fitzcharles M-A. Medical cannabis for older patients. Drugs Aging. 2019;36:39-51.

109 Choi NG, Marti CN, DiNitto DM, et al. Older adults’ marijuana use, injuries, and emergency department visits. Am J Drug Alcohol Abuse. 2018;44:215-23.

110 Maharajan MK, Yong YJ, Yip HY, et al. Medical cannabis for chronic pain: can it make a difference in pain management? J Anesth. 2020;34:95-103.

111 Zalesky A, Solowij N, Yücel M, et al. Effect of longterm cannabis use on axonal fibre connectivity. Brain. 2012;135:2245-55.

112 Choi NG, Marti CN, DiNitto DM, Choi BY. Older adults’ marijuana use, injuries, and emergency department visits. Am J Drug Alcohol Abuse [Internet]. 2018;44(2):215-23. Available from:

113 Maharajan MK, Yong YJ, Yip HY, Woon SS, Yeap KM, Yap KY, et al. Medical cannabis for chronic pain: can it make a difference in pain management? J Anesth [Internet]. 2020;34(1):95-103. Available from:

114 Zalesky A, Solowij N, Yücel M, Lubman DI, Takagi M, Harding IH, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain. 2012;135(7):2245-55.

Submitted date:

Accepted date:

6108020ba95395450a194603 rba Articles

Braz J Anesthesiol

Share this page
Page Sections